enVVeno Medical Corporation (NVNO)
| Market Cap | 69.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.33M |
| Shares Out | 17.54M |
| EPS (ttm) | -1.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,620 |
| Open | 3.960 |
| Previous Close | 3.950 |
| Day's Range | 3.910 - 4.040 |
| 52-Week Range | 2.028 - 6.480 |
| Beta | 0.94 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2025 |
About NVNO
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company’s lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based repla... [Read more]
Financial Performance
Financial StatementsNews
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects main...
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, ...
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous comp...
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the i...
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
IRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasda...
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, tod...
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of...
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of...
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision ...
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a cli...
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP ...
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial...
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Redu...
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, No...
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaf...
Hancock Jaffe To Rebrand As enVVeno Medical
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1. The Company will also narrow its strategic focus...
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the Ven...
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Ja...
Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Hancock Jaffe Laboratories develops nature-mimetic bioprosthetics for patients with debilitating cardiovascular diseases. The Company got IDE approval in April 2021 to begin a pivotal trial of VenoVal...
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enter...
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing ha...
Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device
The FDA has granted Breakthrough Device Designation status to Hancock Jaffe Laboratories Inc's (NASDAQ:HJLI) VenoValve, the Company's lead product, currently set to begin its U.S. pivotal trial. The...
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVV...